Keith Crandell
InvestorCo-Founder and Managing Director at ARCH Venture Partners
Chicago, Illinois
Writes $50K – $150M checks · typically $25M
Founded908 DevicesAdesto TechnologiesArbor BiotechnologiesCytrellis BiosystemsNanosysQuanterix
About
Keith Crandell follows a follow-the-science approach, prioritizing powerful scientific platforms and tools-focused investments, arguing that better, faster, cheaper measurements—echoing the semiconductor measurement revolution—enable biotech breakthroughs.
Invests in
AI & Machine LearningBiotechDeep TechHardwareHealthtechMedical Devices
Deals · 7
Arbor BiotechnologiesBoard seat
via ARCH Venture Partners · filed Nov 2021 · $215M raise
Cytrellis BiosystemsBoard seat
via ARCH Venture Partners · filed Jan 2021 · $50M raise
QuanterixBoard seat
via ARCH Venture Partners · filed Jul 2019 · $6.5M raise
Twist BioscienceBoard seat
via ARCH Venture Partners · filed Dec 2017 · $75M raise
Adesto TechnologiesBoard seat
via ARCH Venture Partners · filed Sep 2015 · $12.5M raise
908 DevicesBoard seat
via ARCH Venture Partners · filed May 2015
NanosysBoard seat
via ARCH Venture Partners · filed Mar 2015 · $10M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at ARCH Venture Partners
Network1
Investors connected to Keith in public investor directories — a warm-intro map.